A Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Oral Administration of a Heat-Treated Lactobacillus paracasei Supplement in Infants with Atopic Dermatitis Receiving Topical Corticosteroid Therapy

被引：26

作者：

Yan, Dah-Chin ^{[1
]}

Hung, Chih-Hsing ^{[2
]}

Sy, Leticia B. ^{[3
]}

Lue, Ko-Huang ^{[4
]}

Shih, I-Hsin ^{[5
]}

Yang, Chin-Yi ^{[5
]}

Chen, Li-Chen ^{[5
]}

Sun, Hai-Lun ^{[4
]}

Lee, Min-Sheng ^{[6
]}

Chambard, Julie ^{[7
]}

Tanguy, Jerome ^{[7
]}

Hughes-Formella, Betsy

Nutten, Sophie ^{[7
]}

Blanchard, Carine ^{[7
]}

机构：

[1] Taipei Chang Gung Mem Hosp, Taipei, Taiwan

[2] Kaohsiung Municipal Hsiaokang Hosp, Kaohsiung, Taiwan

[3] Cardinal Tien Hosp, New Taipei, Taiwan

[4] Chung Shan Med Univ Hosp, Taichung, Taiwan

[5] Linkou Chang Gung Mem Hosp, Taoyuan, Taiwan

[6] Kaohsiung Municipal Tatung Hosp, Kaohsiung, Taiwan

[7] Nestle Res, Lausanne, Switzerland

来源：

SKIN PHARMACOLOGY AND PHYSIOLOGY | 2019年 / 32卷 / 04期

关键词：

Probiotic; Lactobacillus paracasei; Atopic dermatitis; Topical corticoid; TEWL; IDQOL; SCORAD; Objective SCORAD; IgE; CCL17; PROBIOTIC STRAINS; STRATUM-CORNEUM; SCORAD INDEX; DRY SKIN; CHILDREN; LIFE; IGE;

D O I：

10.1159/000499436

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

Background/Aims: Atopic dermatitis (AD) is a common disease in infancy, for which topical steroids are the first-line therapy but have side effects. Innovative approaches are needed to reduce the burden of AD and corticosteroid usage in infants. Methods: The once-daily consumption of heat-treated probiotic Lactobacillus paracasei GM-080 or placebo for 16 weeks as supplementary approach to topical treatment with fluticasone propionate cream was compared in AD infants aged 4-30 months. Outcomes were SCORAD and its subscores, TEWL, Infants' Dermatitis Quality of Life Index (IDQOL), corticoid "sparing effect," CCL17/TARC, and IgE status. Results: SCORAD, objective SCORAD, itching, and IDQOL decreased significantly (p < 0.001) over the treatment period in both treatment groups. Slight decreases (ns) were noted in TEWL in lesional and unaffected skin and CCL17 levels. There were no differences between the treatment groups. Total IgE increased over the treatment period in both groups, with significantly higher increase in the heat-treated probiotic group (p = 0.038). There was no evidence of a corticoid "sparing effect" by the probiotic. Conclusions: In this design, the probiotic L. paracasei was not beneficial as a complementary approach to topical corticosteroids in infants with AD. However, slight beneficial effects may have been masked by the moderate potency corticoid. (c) 2019 S. Karger AG, Basel

引用

页码：201 / 211

页数：11